Introduction
The underlying pathology of Alzheimer's disease is believed to precede the onset of clinical symptoms by many years (Thal et al., 2002) . It has been hypothesized that the formation and accumulation of b-amyloid (Ab) in the Alzheimer's disease brain triggers a cascade of neurodegenerative events, including inflammatory processes, oxidative stress, neurofibrillary tangles, neuronal network dysfunction with synaptic loss and neurotransmitter deficits (Braak and Braak, 1991; Nordberg, 2001; Thal et al., 2002; Ingelsson et al., 2004; Mattson, 2004; Price et al., 2009) , which are manifested clinically by progressive impairment of cognitive functions. Previously, a definite diagnosis of Alzheimer's disease was considered only possible by post-mortem histopathological analysis of the brain; however, the development of new biomarkers including the amyloid positron emission tomography (PET) tracer Pittsburgh Compound B ( 11 C-PIB) for visualizing fibrillar Ab, has created new possibilities for early detection of brain impairments. Several 11 C-PIB PET studies in different cohorts of patients have shown a consistent high load of fibrillar Ab in large parts of the Alzheimer's disease brain compared to healthy controls and other forms of dementia . Longitudinal amyloid imaging studies in subjects with mild cognitive impairment and Alzheimer's disease have suggested that the fibrillar Ab levels in the brain reach a plateau early on and remain stable during the disease progression, whereas neurodegeneration and clinical decline measured by 18 F-fluorodeoxyglucose ( 18 F-FDG), MRI and cognitive tests accelerate and proceed independently of amyloid accumulation (Engler et al., 2006; Forsberg et al., 2008 Forsberg et al., , 2010 Jack et al., 2009; Scheinin et al., 2009; Furst et al., 2010; Kadir et al., 2010) . It has also been shown that the retention of 11 C-PIB in vivo correlates well with autopsy measures of Ab deposition in the Alzheimer's disease brain, but not with tau (Ikonomovic et al., 2008) . We aimed to understand the relationship between clinical and pathological interactive mechanisms by investigating fibrillar Ab accumulation, inflammatory processes and the cholinergic neurotransmitter system in an Alzheimer's disease brain, because these may be validated as PET biomarkers to reflect early changes as well as disease progression.
A 56-year-old female patient with Alzheimer's disease volunteered in February PET imaging scans were assessed in relation to the autopsy data for Ab plaques and neurofibrillary tangle distribution, as well as other pathological markers known to affect brain network function, including markers of inflammation (activated microglia and astrocytes) and neuronal nicotinic acetylcholine receptor losses in different brain regions.
Case history and methods

Clinical description
In 1999, a female patient aged 53 years, was referred from a local hospital to the Department of Geriatric Medicine at Karolinska University Hospital Huddinge, Stockholm, Sweden. The patient had no known family history of dementia or other neurodegenerative diseases. In addition to the patient's own experience of cognitive problems a couple of years prior, during her occupation as a nurse, relatives confirmed difficulties with memory, both at work and at home. The patient underwent a thorough clinical investigation including medical history, cognitive screening, physical and neurological examinations as well as laboratory blood tests, including apolipoprotein E genotyping, neuropsychological assessment, lumbar puncture, electroencephalography (EEG), computed tomography (CT) and single photon emission computed tomography imaging (SPECT). The CT scan was normal; however, the SPECT scan showed decreased cerebral perfusion bilateral in the parietal cortex, predominantly on the left side. EEG investigation showed decreased alpha amplitude as well as theta/delta activity. Analysis of cerebrospinal fluid (CSF) biomarkers revealed pathological values with Ab42 438 pmol/ml (5450 pmol/ml is abnormal) and tau 1180 pmol/ml (4400 pmol/ml is abnormal). The patient was an ApoE e 4/4 carrier. The clinical diagnosis of Alzheimer's disease was made in accordance with the criteria from the workgroup formed by the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's disease and Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984) . The patient received treatment with the cholinesterase inhibitor rivastigmine (12 mg daily) and at a more advanced stage of the disease, she was also treated with memantine (20 mg daily).
The patient was clinically assessed (by A.N.), every 6 months from 1999 to 2007. The patient lived at home with her family until she was admitted to a nursing home, 4 months prior to her death at 61 years of age. Consent from next of kin was given for research studies prior to autopsy. . Detailed information regarding the abovementioned tests has been described previously (Almkvist and Tallberg, 2009) . In order to make comparisons between various neuropsychological test results, all cognitive raw scores were ztransformed by using reference data from healthy adults at the Geriatric Clinic, Karolinska University Hospital Huddinge (Bergman et al., 2007) .
Neuropsychological assessments
Magnetic resonance imaging
MRI was performed at the age of 53 using a 1.5 T scanner (Magnetom Vision Plus, Siemens, Germany) and included a T 1 -weighted 3D magnetization-prepared rapid gradient echo sequence (MP-RAGE), repetition time: 11.4 ms, effective echo time: 4.4 ms, flip angle: 10 , slice thickness: 2.5 mm.
Medial temporal lobe atrophy was assessed visually according to the Scheltens scale (Scheltens et al., 1992) on coronal 3D magnetization-prepared rapid gradient echo sequence slices perpendicular to the anterior commissure and the posterior commissure line at the mid-level of the brainstem after having amygdala in front.
The medial temporal lobe atrophy scale ranges from 0 (no atrophy) to 4 (severe atrophy) and takes into account the width of the choroidal fissure, the height of the hippocampus and the width of the temporal horn of the lateral ventricle. Left and right medial lobe atrophy was rated separately. A trained rater, who was blinded to the clinical information of this case, rated the medial temporal lobe atrophy.
Positron emission tomography
The PET examinations with 18 F-FDG and 11 C-PIB were performed at Uppsala Academic Hospital, Sweden. Production of 18 F-FDG and 11 C-PIB was carried out according to standard manufacturing processes and synthesis of 11 C-PIB was performed by means of a previously described method (Mathis et al., 2003; Klunk et al., 2004) . F-FDG PET scans at ages 53, 56 and 58 years. The PET scans were performed using Siemens ECAT EXACT HR + scanners (CTI PET-Systems, Inc., Knoxville TN, USA) with an axial field of view of 155 mm, providing 63 contiguous 2.46 mm slices with 5.6 mm transaxial and 5.4 mm axial resolution. The patient was scanned under resting condition after fasting for 4 h. The orbito-meatal line was used to centre the heads of the subject. The data were acquired in a 3D mode. The administered mean 18 F-FDG tracer dose was 210 MBq. The scanner protocol for transmission, emission and reconstruction has been described previously (Klunk et al., 2004; Engler et al., 2006) .
Parametric maps of regional cerebral glucose metabolism were generated by means of the Patlak method using the time course of the tracer in the arterialized venous plasma samples as an input function (Patlak et al., 1983) . The frames from 20 to 60 min and a lumped constant of 0.418 were used to generate the parametric maps of regional cerebral glucose metabolism. All values are expressed in mmol/min/100 g.
Positron emission tomography scanning:
11 C-Pittsburgh Compound B
In February 2002, the patient underwent the first 11 C-PIB PET scan at 56 years of age, with an additional 11 C-PIB PET scan performed in August 2004, at 58 years of age. The protocols for the 11 C-PIB PET examinations, including the scanner protocol for transmission, emissions and reconstructions are described in detail in the above-mentioned studies (Klunk et al., 2004; Engler et al., 2006) . The 11 C-PIB examinations were performed using a Siemens ECAT EXACT HR + scanner (CTI PET-systems Inc.), with an axial field of view of 155 mm, providing 63 contiguous 2.46 mm slices with a 5.6 mm transaxial and a 5.4 mm axial resolution. The mean tracer dose of 11 C-PIB was 320 MBq. The 11 C-PIB retention data were calculated as standard uptake values as previously described in detail (Klunk et al., 2004) and were obtained in a late time interval (40-60 min).
reference region. The cerebellar cortex was chosen as the reference region because of its previously reported lack of Congo redand thioflavin-S-positive plaques (Yamaguchi et al., 1989; Mirra et al., 1994) . Voxel-wise two-sample t-test for comparison between-group (patient with Alzheimer's disease versus healthy controls) was computed at the three time points, with P-values uncorrected for multiple comparisons. The brain areas that showed glucose hypometabolism at a peak threshold of P = 0.001 (uncorrected) and an extent threshold of 50 voxels were investigated. For visualization of the t-score statistics (statistical parametric mapping tmap), the significant voxels were projected onto the 3D rendered brain thus allowing anatomical identification. The Montreal Neurological Institute coordinates of the local maximum of each cluster were converted into Talairach coordinates (Talairach and Tournoux, 1988) .
Statistical parametric mapping methods
Neuropathology and immunohistochemistry
The brain was obtained with a post-mortem delay of 17 h. At autopsy, small samples from nine regions of interest: the frontal, temporal, parietal and occipital cortices, the anterior and posterior part of the hippocampus, striatum, thalamus and the cerebellum were collected from the left hemisphere and frozen at À 70 C. The semiquantitative analysis was assessed by the frequency of senile plaques, neurofibrillary tangles and astrocytes in areas of maximum density as described previously (Mirra et al., 1991; Cummings et al., 1996) . The densities were expressed as the absence of immunoreactivity ( À ), rare number of profiles ( + ), sparse number of profiles ( + + ), moderate number of profiles ( + + + ), frequent profiles ( + + + + ) and extensive or widespread profiles ( + + + + + ) ( Table 1 ). In each of the nine regions of interest, the number of senile plaques, neurofibrillary tangles and astrocytes was counted and the total number was averaged from each region of study. All sections were imaged sequentially under light microscopy and counted in Â200 magnification during a single session to prevent changes in illumination or video camera setup. 
Measurement of b-amyloid levels
Neurochemical binding and enzyme assays
Fresh-frozen autopsy tissue samples (grey matter) from the nine regions of interest were homogenized in cold 0.32 M sucrose containing protease inhibitors. The homogenates were aliquoted and frozen at À 80 C until the binding assays were carried out. H-L-deprenyl (10 nM, specific activity 80 Ci/mmol, Larodan Fine Chemicals AB, Malmö , Sweden) (Jossan et al., 1991a) . Specific binding values were expressed as fmol/mg tissue or fmol/mg protein. Butyrylcholinesterase activity was measured by using a modified Ellman's colorimetric assay as described by Darreh-Shori et al. (2006) .
Analysis of in vivo and in vitro correlations
To match the regional autopsy values from the nine different regions of interest with the corresponding regional 11 C-PIB PET retention and 18 F-FDG PET uptake values, the corresponding regions of interest were first drawn in accordance with the Brain Net Europe guidelines (Alafuzoff et al., 2006) on the same MRI coronal levels with the necessary adjustments for exclusion of white matter. Thereafter, the regions of interest were copied onto the coregistered 11 C-PIB and 18 F-FDG-PET scans. Supplementary Figure 1 illustrates the placement of regions of interest on coronal hemispheres and how these regions of interest were used in the correlation analyses. Data from the last 11 C-PIB (standard uptake value) and 18 F-FDG PET (mmol/min/100g), 35 months prior to death, were used in correlations with data obtained from measurements performed in the autopsy brain tissue.
Statistical analysis
In sum, 43 correlations were performed across this entire study ( H-nicotine versus three parameters; 125 I-a-bungarotoxin versus three parameters). Correlation analyses were performed by using non-parametric Spearman's rank order correlation. Due to the explorative nature of the study and the low statistical power (as nine brain regions were used in the correlations), statistical Bonferroni correction for multiple comparisons yielding a significant level 0.0012 (0.05/43) was not carried out. The level of statistical significance was set at 0.05 (two-sided). This implies that the results should be interpreted with some caution.
In addition, stepwise regression analysis was performed to determine correlations between cognitive test performances and regional cerebral glucose metabolism as measured by 18 F-FDG PET in various brain areas during the progression of disease (age 53-58 years).
Results
Longitudinal study of cognition, 18 F-fluorodeoxyglucose uptake and 11 C-Pittsburgh Compound B retention by positron emission tomography
The first neuropsychological assessment of the patient with Alzheimer's disease, at 53 years of age, revealed significant cognitive impairment, particularly in visuospatial ability, short-term memory and executive functioning, while verbal ability was preserved (Fig. 1A) . The mini-mental state examination score was 27 out of 30 during the first visit to the Geriatric Clinic at age 53, and progressively declined over the course of the disease with a score of 5 out of 30 during the last cognitive assessment at the age of 60 years. The pattern of decline in mini-mental state examination scores was best-fit to a curvilinear regression line (r = 0.97, Fig. 1B ). Progressive decline was longitudinally observed in other cognitive tests such as global cognition, episodic memory and attention (Fig. 1C) .
The MRI scan was performed as part of the clinical assessment at 53 years of age. No infarction or haemorrhage was noted. The patient had discrete bilateral parietal atrophy ( Fig. 2A and B) , and for the hippocampus, the medial temporal lobe atrophy score was 1 (left side) and 1-2 (right side) (Fig. 2C) .
Voxel-based analysis of 18 F-FDG-PET using statistical parametric mapping was performed to visualize the decline in regional cerebral glucose metabolism in the patient, compared with that from a group of healthy control subjects. The 3D-rendered image of the voxel mapping showed significant decreases in regional cerebral glucose metabolism in certain brain regions (right hemisphere: superior parietal lobule, inferior parietal lobule, precuneus, superior frontal gyrus, inferior frontal gyrus, superior temporal gyrus, parahippocampal gyrus and fusiform gyrus; left hemisphere: inferior parietal lobule, superior frontal gyrus; all P = 0.001 uncorrected, k = 50) at the first 18 F-FDG-PET scan at 53 years of age (Fig. 3A) .
In line with the cognitive decline, there was also a pronounced decrease in regional cerebral glucose metabolism with disease progression as illustrated with voxel-based statistical parametric mapping analysis at 56 and 58 years of age, compared with the healthy control group ( Fig. 3B and C) . By using the stepwise regression analysis, we observed that regional cerebral glucose metabolism, in three areas of the brain that are affected early on in the disease course (medial temporal, posterior cingulate and lower parietal), significantly correlated (P 5 0.05) with test scores for attention, episodic memory and FSIQ during progression of the disease (Fig. 4) .
The first 11 C-PIB scan at 56 years of age (mini-mental state examination 21/30) showed high 11 C-PIB retention especially in the frontal, parietal, parietotemporal, temporal, posterior cingulate and in the striatum ( Fig. 5A and B) . At 2 year follow-up (mini-mental state examination 13/30), the cortical 11 C-PIB retention remained high and relatively unchanged ( Fig. 5A and B) , in contrast to the continuous decline observed in regional cerebral glucose metabolism paralleling the decline in cognitive performance (Figs 1 and 3 ).
Semi-quantitative immunohistochemical assessment of neuropathology at autopsy
The brain weighed 1100g. Macroscopic inspection showed a widening of sulci and cortical and hippocampal atrophy. The anterior part of the hippocampus had a particularly reduced size and the ventricles were slightly enlarged. The histopathological examination revealed a pure Alzheimer's disease pathology (Braak stage 6, definite CERAD) confirming the clinical diagnosis of Alzheimer's disease. Congo red staining showed several positive vessels in the leptomeninges and the cortex, consistent with cerebral amyloid angiopathy.
Immunohistochemical assessment of the regional distribution of different types of Ab-containing plaques showed varied staining patterns with Ab antibodies with different epitope specificity. More plaques were stained with antibodies for Ab1-42, 4G8 (reactive to amino acid residue 17-24) and 6F/3D (residue 8-17) when compared with antibodies for Ab1-40 and 6E10 (residue 1-17) ( Fig. 6A-E) . 4G8 labelled both plaques and intracellular Ab deposits in all the regions studied. A high distribution of intracellular Ab was detected by 4G8 in the hippocampus (score F-FDG-PET images. Areas of red depict areas in which the regional cerebral glucose metabolism was significantly decreased in the patient with Alzheimer's disease at the age of 53, 56 and 58 years compared with a group of healthy control subjects (P = 0.001, uncorrected, k = 50). MMSE = mini-mental state examination. + + + + + ) compared to cortical regions (score + + + ). Numerous cortical plaques were detected in the parietal cortex (score + + + + + with Ab1-42 and 6F/3D and score + + + + with 4G8), and the frontal cortex (score + + + + with all three antibodies), consistent with the neuropathological diagnosis (Table 1) . In contrast, a diffuse distribution of senile plaques was observed in the hippocampus, striatum, thalamus and cerebellum (ranging in score from + + to À with all antibodies). Neurofibrillary tangles were prominent in the anterior hippocampus (score + + + + + , Fig. 6G and H) and scattered in the frontal, parietal and the occipital lobe cortices. In the hippocampus, an overlap between areas with high tau AT8 immunoreactivity and intracellular 4G8 staining was observed (Table 1) . Glial fibrillary acidic protein immunoreactivity was higher in cortical regions in comparison to non-cortical regions and reactive astrocytes were observed in areas with large amounts of amyloid plaque clusters (Fig. 6F) . Many of the vessels in the leptomeninges and cortex were stained with the amyloid antibodies. There was a variation in the number of stained vessels with the antibodies used, most abundant with Ab1-40.
Regional
11 C-Pittsburgh Compound B positron emission tomography retention and b-amyloid levels at autopsy
The regional 11 C-PIB retention measured by PET, at both 56 and 58 years of age, showed a positive correlation with the regional 3 H-PIB binding (P 5 0.001) as well as the total insoluble Ab levels (P 5 0.01) measured in autopsy brain tissue ( Fig. 7A and B) . A high fibrillar amyloid load visualized with 11 C-PIB PET in the frontal and parietal cortex corresponded with the highest measured 3 H-PIB binding as well as the highest levels of total insoluble Ab in these same regions at autopsy. Across nine brain regions, in vivo 11 C-PIB retention showed significant positive correlations with semi-quantitative neuropathological assessment of Ab antibody 6F/3D (P 5 0.001), Ab 1-42 (P 5 0.02) and extracellular Ab 4G8 (P 5 0.02) immunoreactivity (Supplementary Fig. 2A-C) . Similarly, significant positive correlations were also observed in in vitro 3 H-PIB binding and 6F/3D
(P 5 0.02), Ab 1-42 (P 5 0.008) and extracellular Ab 4G8 (P 5 0.05) immunoreactive plaques ( Supplementary Fig. 2D-F) . No significant correlation was observed between in vivo 11 C-PIB retention or 3 H-PIB binding and intracellular 4G8-stained Ab.
11 C-Pittsburgh Compound B, 18 F-fluorodeoxyglucose positron emission tomography and regional distribution of neurofibrillary tangles at autopsy
There was no correlation between regional distribution of in vivo 11 C-PIB retention or 3 H-PIB binding and AT8 tau immunopositive staining for neurofibrillary tangles in autopsy brain (data not shown). A weak non-significant negative correlation (P 5 0.07) was observed between in vivo regional cerebral glucose metabolism as measured by 18 F-FDG PET and neurofibrillary tangles ( Supplementary Fig. 3 ), which was driven by the anterior and posterior hippocampus, reflecting the predominance of neurofibrillary tangles in these regions.
11 C-Pittsburgh Compound B positron emission tomography retention, 3 H-Pittsburgh Compound B and 3 H-nicotine binding at autopsy Figure 8A illustrates the low number of 3 H-nicotine binding sites (a4b2 neuronal nicotinic acetylcholine receptors) especially in cortical regions (frontal, parietal and temporal) of the Alzheimer's disease brain in comparison with the regional 3 H-nicotine binding in an age-matched control group (historical data from our research laboratory). A weak negative correlation was observed between regional in vivo 11 C-PIB retention and 3 H-nicotine binding at autopsy (P 5 0.06, Fig. 8B ), while a stronger negative correlation was observed between 3 H-PIB and 3 H-nicotine binding in different brain regions of the autopsy tissue (P 5 0.02, Fig. 8C ). This finding reflects that high fibrillar load is accompanied by a loss of a4b2 neuronal nicotinic acetylcholine receptors in autopsy brain. No significant correlations were observed between in vivo 11 C-PIB retention or 3 H-PIB binding versus 125 I-a-bungarotoxin binding (a7-neuronal nicotinic acetylcholine receptors). 
Discussion
The significant progress in the field of molecular medicine has advanced our knowledge of the sequence of neurodegenerative events in the brain that lead to dementia disorders such as Alzheimer's disease. The development of different diagnostic biomarkers measuring brain Ab and regional cerebral glucose metabolism by PET, and brain atrophy by MRI as well as CSF biomarkers facilitates the early detection of Alzheimer's disease Frisoni et al., 2010; Nordberg et al., 2010) . The clinical benefits of CSF biomarkers and 11 C-PIB PET imaging for early diagnosis of prodromal stages of Alzheimer's disease were recently recommended in the National Institute on Ageing-Alzheimer Association draft diagnostic criteria guidelines (http://www.alz.org/reaearch/diagnostic_criteria). While biomarker studies may provide insight into the dynamic relationships between Alzheimer's disease pathology, neurodegeneration and cognition, autopsy studies are important for a secure foundation on which to base further understanding of the cellular and molecular changes that contribute to Alzheimer's disease (Esiri, 2010; Jellinger, 2010) .
The patient with Alzheimer's disease described in this study volunteered for the first 11 C-PIB PET scan in the world, in February 2002. The patient was clinically followed at regular intervals until her death. Post-mortem neuropathological examination performed 35 months after the last 11 C-PIB-PET scan confirmed the clinical diagnosis of Alzheimer's disease with a pure Alzheimer's disease pathology at autopsy. The patient showed a continuous deterioration in cognitive performance, which paralleled the decline in regional cerebral glucose metabolism as observed at threerepeated 18 F-FDG scans. Meanwhile, 11 C-PIB retention remained stable between baseline and the 2 year follow-up, which is in agreement with reports from other follow-up studies with 11 C-PIB in patients with Alzheimer's disease after one year (Jack et al., 2009; Scheinin et al., 2009) , 2 years (Engler et al., 2006) and a 5 year follow-up . In this study, we did not observe any regional correlation between 11 C-PIB retention and regional cerebral glucose metabolism. However, previous studies have reported an inverse relation between 11 C-PIB retention and regional cerebral glucose metabolism, especially in the parietal cortex (Klunk et al., 2004; Engler et al., 2006; Edison et al., 2007) . A high fibrillar Ab plaque as measured by 11 C-PIB was present in this patient with Alzheimer's disease, most notably in cortical regions. We demonstrated that 11 C-PIB retention measured by PET at 56 and 58 years of age significantly correlated with region-matched autopsy quantification of Ab, measured by both 3 H-PIB binding and enzyme-linked immunosorbent assay detection of total levels of insoluble Ab (Ab40 and Ab42). Two other studies have reported correlations between in vivo 11 C-PIB retention and Ab deposited in autopsy brains (Bacskai et al., 2007; Ikonomovic et al., 2008) . Bacskai et al. (2007) C-PIB-PET imaging, and brain autopsy performed 10 months later. In addition, patients with high fibrillar Ab levels in frontal cortical biopsy specimens have shown high 11 C-PIB retention in the brain 3 years later (Leinonen et al., 2008) . Altogether, these studies confirm that 11 C-PIB retention in the brain is associated with levels of insoluble, but not soluble Ab. Similar results have been obtained in in vitro studies with PIB binding to synthetic Ab fibrils and insoluble Ab deposits in human post-mortem brain tissues (Klunk et al., 2005; Bacskai et al., 2007; Lockhart et al., 2007; Ikonomovic et al., 2008; Cairns et al., 2009; Svedberg et al., 2009 ). Subsequently, we examined in detail the regional distribution of Ab plaques in the autopsy brain with immunohistochemistry using five antibodies with different specificity for amino acid residues reactive to the human Ab peptide. The distribution revealed large extracellular deposits of Ab plaques in cortical areas that correlated significantly with both 11 C-PIB retention measured by 
P<0.01
In vivo 11 C-PIB retention (SUV) lt hemisphere
In vivo 11 C-PIB retention (SUV) lt hemisphere detected in sections from human Alzheimer's disease neocortex have been reported in other studies, where investigators used some of the same antibodies applied in this study (Klunk et al., 2004; Lockhart et al., 2007; Ikonomovic et al., 2008) . By using the 4G8 antibody, we found higher intracellular Ab deposition in the hippocampus than in other brain areas. This observation suggests that there may be differences in the brain regions regarding the internal and external localization of Ab, as a consequence of the disease state or tissue characteristics. Alternatively, we suggest that these differences observed in 4G8 immunoreactivity could be related to the vulnerability of specific populations of cells in some regions of the brain and to the dynamic relationship between the pools of intracellular and extracellular Ab. It has been suggested that intracellular accumulation of Ab interfering with the synaptic activity, occurs prior to extracellular accumulation forming the Ab plaques (Tampellini and Gouras, 2010) . The 11 C-PIB retention did not correlate with intracellular Ab. This probably reflects that PIB binds preferentially to extracellular fibrillar Ab and less to intracellular Ab; however future studies investigating this issue as well PIB binding to other forms of Ab, such as various Ab oligomers, are warranted.
The hippocampus is a region that typically shows dense neurofibrillary tangle distribution (Thangavel et al., 2009) , which was evident in this study by the widespread and characteristic distribution pattern of neurofibrillary tangles in this specific region in the autopsy tissue. The reduction of regional cerebral glucose metabolism in susceptible brain regions measured in vivo by 18 F-FDG PET paralleled the finding of an increased number of neurofibrillary tangles in the hippocampus, probably as a marker of neurodegeneration, synaptic activity and clinical progression of Alzheimer's disease (Ingelsson et al., 2004; Engler et al., 2006; von Gunten et al., 2006; Kadir et al., 2010) . We found no correlation between 11 C-PIB retention and the number of neurofibrillary tangles in either the cerebral cortex or the hippocampus, confirming the earlier observation by Ikonomovic et al. (2008) , who also demonstrated the possibility of PIB binding in vitro to a subset of extracellular (ghost) tangles in the entorhinal cortex.
Congo red staining in autopsy brain of this patient with Alzheimer's disease showed several positive vessels in the leptomeninges and the cortex consistent with cerebral amyloid angiopathy, which is commonly observed in patients with Alzheimer's disease. In a series of autopsy cases, covering 117 subjects with clinical Alzheimer's disease, $80% had demonstrable Ab deposits within blood vessels, (Ellis et al., 1996) . The presence of cerebral amyloid angiopathy was higher in patients with Alzheimer's disease having at least one ApoE e4 allele (Pfeifer et al., 2002) . It has been shown that 3 H-PIB binds to both fibrillar and vascular Ab (Bacskai et al., 2007; Lockhart et al., 2007; Ikonomovic et al., 2008) . In subjects with cerebral amyloid angiopathy, vascular Ab could be a major contributor to the in vivo 11 C-PIB signal Ly et al., 2010) . However, cerebral amyloid angiopathy pathology has an occipital predilection, resulting in a greater occipital 11 C-PIB retention compared to patients with Alzheimer's disease Ly et al., 2010) . Although we found that Ab was present in the blood vessels in the autopsy Alzheimer's disease brain, we consider that 11 C-PIB binding to cerebral amyloid angiopathy contributed very little to the total in vivo 11 C-PIB retention. The impairment of the cholinergic neurotransmitter system is well established in Alzheimer's disease. We have earlier demonstrated significant losses of neuronal nicotinic acetylcholine receptors, especially a4b2 neuronal nicotinic acetylcholine receptors, in autopsy studies of Alzheimer's disease brain tissue as well as by 11 C-nicotine PET (Paterson and Nordberg, 2000) . Moreover, we have verified with 11 C-nicotine PET that the cortical decline in 11 C-nicotine binding observed in vivo correlates with the cognitive impairment of the patients with Alzheimer's disease . Reports from several experimental studies also suggest a link between brain neuronal nicotinic acetylcholine receptors and Ab accumulation in Alzheimer's disease (D'Andrea et al., 2001; Dineley et al., 2002; Nagele et al., 2002; Dougherty et al., 2003; Clifford et al., 2008) . In the present study, we quantified two of the major neuronal nicotinic acetylcholine receptor subtypes (a4b2 and a7 neuronal nicotinic acetylcholine receptors) in different brain regions of the autopsy tissue in the patient with Alzheimer's disease. Low 3 H-nicotine binding was measured in brain regions with high 11 C-PIB retention, and a strong correlation was found between 3 H-PIB and 3 H-nicotine binding at autopsy. In an unrelated PET study, including a cohort of seven patients with mild Alzheimer's disease, we observed a significant negative correlation between 11 C-PIB retention and 11 C-nicotine binding (unpublished observations), which supports our current findings in autopsy brain tissue. The stronger correlation between 3 H-nicotine and 3 H-PIB at autopsy compared with 11 C-PIB in vivo may be due to the gradual loss of neuronal nicotinic acetylcholine receptors occurring during Alzheimer's disease progression (neurodegeneration) in comparison to the relatively stable Ab levels measured by 11 C-PIB PET ). An alternative explanation is that there might be a slight difference in Ab measured by 11 C-PIB compared with 3 H-PIB. It is possible that studies with 3 H-nicotine binding at autopsy might more readily detect this difference. This new observation regarding a4b2 neuronal nicotinic acetylcholine receptors and fibrillar Ab is of great interest, and further studies are required to validate this finding and to elucidate the role of neuronal nicotinic acetylcholine receptors in amyloid pathology. Experimental studies have previously demonstrated that soluble forms of Ab bind to a7 neuronal nicotinic acetylcholine receptors (Liu et al., 2001; Lee and Wang, 2003; Lilja et al., 2010) . It has previously been shown that the a7 neuronal nicotinic acetylcholine receptors are present both on neurons as well as on glia cells, and these receptors have been reported to be reduced on neurons in autopsy brain tissue from patients with Alzheimer's disease (Yu et al., 2005) and increased on astrocytes (Teaktong et al., 2003; Yu et al., 2005) . Although an increased number of a7 neuronal nicotinic acetylcholine receptors in autopsy brain tissue from patients with Alzheimer's disease with high Ab load in brain was recently reported ), we did not observe any correlation between either regional 11 C-PIB retention in vivo or 3 H-PIB and a7 neuronal nicotinic acetylcholine receptors as measured by 125 I-a-bungarotoxin binding in the present study. It may be difficult in tissue homogenates to distinguish between a7 neuronal nicotinic acetylcholine receptors localized on neurons versus astrocytes, which could be a possible explanation as to why we did not observe any correlation with fibrillar Ab levels.
The consequence and the time course of inflammatory processes, in relation to fibrillar Ab during the progression of Alzheimer's disease, are still under investigation. Increased numbers of both activated microglial cells and reactive astrocytes are often observed in the vicinity of the fibrillar core of Ab plaques in the Alzheimer's disease autopsy brain (Braak et al., 1998; Zhu et al., 1999) . These observations suggest that the increase in activated microglia and activated astrocytes may reflect attempts by these glial cells to clear Ab in the brain. However, when the disease progresses, they may instead potentiate neurotoxicity by releasing toxic immune mediators (McGeer et al., 2000) .
Increased binding of 3 H-PK-11195, a peripheral-type benzodiazepine binding site ligand, has been measured in homogenates from Alzheimer's disease brains reflecting an increase in microglia/ macrophages (Diorio et al., 1991; Saura et al., 1994) . Similarly, increased monoamine oxidase B activity has been measured in Ab plaque-associated astrocytes with other monoamine oxidase B ligands such as 3 H-lazabemide (Saura et al., 1994) and 3 H L-deprenyl (Jossan et al., 1991b) . Both 11 C-PK11195 and 11 C-L-deuterodeprenyl have been used as PET ligands for visualizing activated microglia and astrocytes, respectively (Cagnin et al., 2001; Engler et al., 2003) in neurodegenerative diseases. While a strong binding signal of these tracers is detected in multiple sclerosis (Debruyne et al., 2003) and Creutzfeldt-Jacob disease (Engler et al., 2003) , the 11 C-PK11195 binding has varied in Alzheimer's disease in different PET studies. Increased binding of 11 C-PK11195 was reported in cortical regions of patients with mild Alzheimer's disease when compared with healthy controls (Cagnin et al., 2001) . In more recent PET studies, low 11 C-PK1195 binding was measured in patients with Alzheimer's disease and mild cognitive impairment (Okello et al., 2009; Wiley et al., 2009) . Increased 11 C-PK1195 binding was observed by Edison et al. (2008) in regions associated with high 11 C-PIB retention, further demonstrating an inverse correlation between cognition and levels of cortical 11 C-PK1195 binding measured by PET. In a recent PET study in patients with mild cognitive impairment, the investigators did not find such a correlation between 11 C-PK11195 and 11 C-PIB retention (Okello et al., 2009) . Similarly, we did not observe any relation between 11 C-PIB retention or 3 H-PIB and 3 H-PK1195 binding in the present study. A possible explanation for these different findings with 11 C-PK11195 might be changes in binding affinity during different stages of microglia activation (Vas et al., 2008 ). In the current study, a positive correlation was found between glial fibrillary acidic protein immunopositive cells and in vivo 11 C-PIB retention as well as 3 H-PIB binding and extracellular Ab quantified by immunohistochemistry. This finding supports the assumption that astrocytosis is located in close proximity to fibrillar Ab plaque formation (Simpson et al., 2010) . A positive correlation has been demonstrated between 3 H-lazabemide (monoamine oxidase B inhibitor) and glial fibrillary acidic protein immunoreactivity in the Alzheimer's disease brain (Saura et al., 1994) . We found no relationship between regional C-L-deuterodeprenyl binding in patients with mild cognitive impairment and mild Alzheimer's disease compared to controls (Carter et al., 2010) . No correlation was observed between regional changes in 11 C-L-deuterodeprenyl binding and 11 C-PIB retention or regional cerebral glucose metabolism, respectively (Carter et al., 2010) .
In the present study, we found a positive correlation between regional 3 H-L-deprenyl and butyrylcholinesterase activity, probably reflecting a pathophysiological consequence of butyrylcholinesterase activity on inflammatory processes in the Alzheimer's disease brain (Darreh-Shori et al., 2009 ). An increased brain butyrylcholinesterase activity has been attributed to an increase in the prevalence of reactive glial cells and Ab plaques, to which this enzyme is localized (Perry et al., 1978; Geula and Mesulam, 1995; Lehmann et al., 2000; Tasker et al., 2005) . We have recently observed a strong positive correlation between CSF butyrylcholinesterase activity and cortical 11 C-PIB retention (Darreh-Shori et al., 2010).
Interestingly, 3 H-L-deprenyl, 3 H-PK11195 and butyrylcholinesterase all showed high binding and activity in the hippocampus, a region characterized by a high amount of neurofibrillary tangles as a sign for neurodegenerative processes.
In conclusion, this study confirmed the pure Alzheimer's disease pathology of the first 11 C-PIB PET imaged patient with Alzheimer's disease. We demonstrated a strong correlation between fibrillar Ab measured by PET and at autopsy several years later. Loss of neuronal nicotinic acetylcholine receptors (a4b2 subtype) at autopsy was associated with high levels of fibrillar Ab, suggesting that neuronal nicotinic acetylcholine receptors, as markers for degenerative processes, may closely be linked to Ab pathology. Although, we found a positive correlation between glial fibrillary acidic protein immunoreactivity and fibrillar Ab, measured by PET as well as at autopsy, the lack of a correlation between fibrillar Ab and binding of the two PET tracers PK11195 and deprenyl in autopsy tissue, suggests that these tracers should further be studied in vivo by PET in order to gain a better understanding of the time course for early changes in neuroinflammatory processes in relation to Ab in Alzheimer's disease.
